Viveo raises R$1.8 billion with IPO
In August, leading Brazilian medical supplies distribution company Viveo held its IPO at São Paulo-based stock exchange B3 and raised R$1.8 billion. The IPO included a primary offering of 35,140,562 common shares and a secondary offering of 59,085,356 common shares, which were priced at R$19.92 each.
Viveo was founded in 1996 by the Mafra family, who now controls the operation alongside the Bueno family, founders of the Amil group. Since 2017, the company’s growth was accelerated through several acquisitions, which included personal hygiene group Flexicotton, hospital supplies companies Biogenetix, Vitalab and Byogene, as well as a stake of pharmacotherapy company Far.Me, vaccines manufacturer Tecnocolg and disposable diapers manufacturer Cremer.
Davis Polk & Wardwell advised Viveo in its corporate, tax and investment management matters, and Machado Meyer Advogados (São Paulo) advised Viveo and the selling shareholders.
JP Morgan Securities, Itaú BBA USA Securities, BTG Pactual US Capital, UBS Securities, BofA Securities, Bradesco Securities and Safra Securities acted as international placement agents and hired Simpson Thacher & Bartlett to act in tax and capital markets discussions.
Stocche Forbes Advogados, respectively, advised Banco JP Morgan, Banco Itaú BBA, Banco BTG Pactual, Banco Bradesco BBI, Safra Bank, UBS Brasil Corretora de Exchange, Securities and Bank of America Merrill Lynch Banco Múltiplo as the coordinators of the local offering.
The European Commission’s approval of the copyright directive in April threw more gas on the fire. In a few years, the internet has become – among other things – the main market fo...
The long-serving boss of Cobepa, Jean-Marie Laurent Josi talks about the business model of a Belgian investment firm that is trusted by major European families, one which marries t...
Since the last half of 2008, it is no longer possible to conceal the term ‘crisis’. New paradigms have become apparent and structural changes are predicted. Indeed mar...